| Variables | MDA level (ng/mL) | p-value | |||
| N | Mean (SD) | Median | Range | ||
| Sex |
|
|
|
| 0.997† |
| Male | 19 | 82.6 (18.2) | 85.8 | 47 - 112 |
|
| Female | 12 | 81.5 (17.7) | 84.9 | 52.5 - 105.1 |
|
| Age |
|
|
|
| 0.527† |
| <10 years | 12 | 79 (17.1) | 81.6 | 47 - 98.7 |
|
| ≥10 years | 19 | 82.3 (18.4) | 86.2 | 52.5 - 112 |
|
| Length of illness |
|
|
|
| 0.898* |
| <5 years | 6 | 78.8 (22.2) | 88.1 | 47 - 97.5 |
|
| 5 - 10 years | 10 | 81.2 (14.6) | 86.2 | 54 - 98.7 |
|
| >10 years | 15 | 82,9 (18,8) | 84.7 | 52.5 - 112 |
|
| Type of Thalassemia |
|
|
|
| 0.066† |
| Major | 16 | 87.2 (16.8) | 87.3 | 52.2 - 112 |
|
| Intermedia | 15 | 75.5 (17.2) | 75.2 | 47 - 98.7 |
|
| Thalassemia degrees |
|
|
|
| 0.026† |
| Moderate | 20 | 76.4 (17.3) | 77.7 | 47 - 105.2 |
|
| Severe | 21 | 91 (15) | 95.5 | 65.7 - 112 |
|
| Iron chelating agent |
|
|
|
| 0.902† |
| Deferiprone | 23 | 81.8 (18.8) | 85.8 | 47 - 112 |
|
| Deferasirox | 8 | 80.9 (15.4) | 85.4 | 54 - 100.4 |
|
| Treatment adherence |
|
|
|
| 0.188† |
| Optimal | 15 | 77.2 (19.1) | 80.1 | 47 - 105.1 |
|
| Not optimal | 16 | 85.7 (15.9) | 86.4 | 56.7 - 112 |
|